There was no statistically significant difference among the germline genomic testing of pathogenic variants (BRCA1/2, HRR deficiency, tissue-agnostic, and/or inherited cancer syndrome mutations), variants of unknown significance, negative testing results, or patients who declined to test/were not tested. Here, BRCA1 is linked to hereditary neoplastic syndrome.